Fortress Biotech, Inc. (FBIO)

In the past six months, Fortress Biotech's stock price has been impacted by several events, including the U.S. FDA approval of ZYCUBO in January 2026, which led to a surge in FBIO stock. In December 2025, Fortress Biotech and Cyprium Therapeutics announced the FDA acceptance of the CUTX-101 NDA resubmission, and Fortress Biotech amended its credit agreement with Oaktree. In November 2025, the company reported its Third Quarter 2025 financial results and recent corporate highlights. Over the last year, FBIO shares have experienced a 52-week high of $4.53 and a 52-week low of $1.33. As of February 6, 2026, the closing stock price was $3.27.

Specific detailed information on the demand seasonality for Fortress Biotech's individual products and services is not extensively provided, but general market analysis tools indicate that seasonality can reveal recurring monthly trends in an asset's performance. Seasonality displays mean and median monthly returns to identify patterns. Given the nature of pharmaceutical products, demand might be influenced by factors such as disease prevalence, treatment cycles, and new product launches rather than typical consumer seasonality.

Fortress Biotech, Inc. is a biopharmaceutical company focused on developing and commercializing pharmaceutical and biotechnology products within the Biotechnology sector and Health Care industry. The company aims to generate long-term revenue through product sales, equity holdings, and royalties, with a portfolio that includes nine marketed prescription pharmaceutical products and numerous programs in development across various therapeutic areas, including oncology, dermatology, and rare diseases. The company markets dermatology products such as Emrosi, Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm, Targadox, Luxamend, and Ximino. Fortress Biotech also has a robust pipeline of product candidates, including Intravenous Tramadol, CUTX-101, UNLOXCYT, Olafertinib, CAEL-101, Triplex, and ZYCUBO, which recently received U.S. FDA approval.

Fortress Biotech, Inc. is based in Bay Harbor Islands, Florida, and was incorporated in 2006. The company is traded on the NASDAQ Exchange in the USA, indicating its primary market and operational focus are within the United States.

Fortress Biotech has maintained a positive brand reputation over the past year, particularly within the medical sector, with a news sentiment score of 1.22. The U.S. FDA approval of ZYCUBO in January 2026, marking it as the first and only approved treatment for Menkes disease in the United States, has significantly positively impacted the company's reputation.

The ownership structure of Fortress Biotech (FBIO) includes institutional, retail, and individual investors. Institutional investors, including Vanguard Group Inc., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Summit Financial, LLC, and Nantahala Capital Management LLC, hold approximately 15.04% of the common stock. Insiders retain a significant amount of outstanding shares, holding 15.63% of the common stock, with David Jin owning the most shares among individuals.